KR20070043795A - 톨-유사 수용체 발현 종양 세포에서 세포자멸사의 유도방법 - Google Patents

톨-유사 수용체 발현 종양 세포에서 세포자멸사의 유도방법 Download PDF

Info

Publication number
KR20070043795A
KR20070043795A KR1020077001407A KR20077001407A KR20070043795A KR 20070043795 A KR20070043795 A KR 20070043795A KR 1020077001407 A KR1020077001407 A KR 1020077001407A KR 20077001407 A KR20077001407 A KR 20077001407A KR 20070043795 A KR20070043795 A KR 20070043795A
Authority
KR
South Korea
Prior art keywords
cells
poly
tlr
tlr3
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077001407A
Other languages
English (en)
Korean (ko)
Inventor
세르게 레벡꾸에
토우픽 렌노
부루노 살라운
이사벨 코스테-인베르니찌
마리-끌로띨데 리쏘앙
Original Assignee
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쉐링 코포레이션 filed Critical 쉐링 코포레이션
Publication of KR20070043795A publication Critical patent/KR20070043795A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020077001407A 2004-07-20 2005-07-19 톨-유사 수용체 발현 종양 세포에서 세포자멸사의 유도방법 Ceased KR20070043795A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58961604P 2004-07-20 2004-07-20
US60/589,616 2004-07-20

Publications (1)

Publication Number Publication Date
KR20070043795A true KR20070043795A (ko) 2007-04-25

Family

ID=35229744

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077001407A Ceased KR20070043795A (ko) 2004-07-20 2005-07-19 톨-유사 수용체 발현 종양 세포에서 세포자멸사의 유도방법

Country Status (12)

Country Link
US (2) US20060147456A1 (enExample)
EP (1) EP1768699A1 (enExample)
JP (1) JP2008507530A (enExample)
KR (1) KR20070043795A (enExample)
CN (1) CN101018567B (enExample)
AT (1) ATE511859T1 (enExample)
AU (2) AU2005269733B2 (enExample)
CA (1) CA2574176A1 (enExample)
MX (1) MX2007000770A (enExample)
NO (1) NO20070945L (enExample)
RU (1) RU2401661C9 (enExample)
WO (1) WO2006014653A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101250419B1 (ko) * 2010-12-16 2013-04-05 강원대학교산학협력단 Ｔｌｒ 작동제를 포함하는 유방암 방사선 치료 보조제

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
EP1613775B1 (en) * 2003-03-26 2012-08-29 Multicell Immunotherapeutics, Inc. Selected rna motifs in anti-leukemia therapy
WO2006054129A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US20120189643A1 (en) * 2004-11-30 2012-07-26 Carton Jill M Toll Like Receptor 3 Antagonists, Methods and Uses
SG170041A1 (en) 2006-03-02 2011-04-29 Agency Science Tech & Res Methods for cancer therapy and stem cell modulation
CA2652349A1 (en) 2006-05-15 2007-11-22 University Of Kentucky Research Foundation Toll-like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration
EP1881080A1 (en) * 2006-07-18 2008-01-23 Institut Gustave Roussy Toll like receptor 4 dysfunction and the biological applications thereof
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
JP5115921B2 (ja) * 2007-02-28 2013-01-09 株式会社ペルセウスプロテオミクス 腎癌の診断薬および治療薬
CA2685557A1 (en) * 2007-04-24 2008-10-30 John Wayne Cancer Institute Functional toll-like receptors (tlr) on melanocytes and melanoma cells and uses thereof
CN101909630A (zh) * 2007-11-02 2010-12-08 新加坡科技研究局 预防和治疗肿瘤的方法和化合物
GB2455204B (en) * 2007-11-28 2010-07-14 Smart Tube Inc Devices, systems and methods for the collection, stimulation, stabilization and analysis of a biological sample
JP2011518116A (ja) 2008-02-21 2011-06-23 ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション トール様受容体３拮抗薬としての超小型ｒｎａ
EP2281043B1 (en) 2008-04-25 2013-03-13 Innate Pharma Improved tlr3 agonist compositions
WO2010020590A1 (en) * 2008-08-20 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8
GB0820698D0 (en) * 2008-11-12 2008-12-17 Ludwig Inst Cancer Res Uses of immunomodulators
WO2010068680A1 (en) 2008-12-10 2010-06-17 Mount Sinai School Of Medicine Of New York University Thelper cell type 17 lineage-specific adjuvants, compositions and methods
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
NZ599677A (en) * 2009-12-18 2014-10-31 Bavarian Nordic As Production of ifn-lambda by conventional dendritic cells and uses thereof
AU2012287024A1 (en) * 2011-07-22 2014-02-20 Pawel Kalinski Tumor selective chemokine modulation
CN102652802A (zh) * 2012-04-18 2012-09-05 南京中医药大学 癌毒方在制备调控肝癌细胞TLRs／NF-κB信号转导药物中的应用
WO2014022287A1 (en) * 2012-07-29 2014-02-06 The Regents Of The University Of Colorado, A Body Corporate Antagonists of the toll-like receptor 1/2 complex
WO2015127002A1 (en) * 2014-02-19 2015-08-27 The Johns Hopkins University Compositions and methods for promoting skin regeneration and hair growth
ES2725948T3 (es) 2014-06-04 2019-09-30 Exicure Inc Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas
CN105796594A (zh) * 2016-03-28 2016-07-27 南京大学 一种组合物在制备治疗肿瘤药物中的应用及该组合物的使用方法
CN106191238B (zh) * 2016-07-08 2020-01-10 中国医学科学院基础医学研究所 Tlr3预测肿瘤转移、评估预后和选择防治方案的应用
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CN108295060A (zh) * 2018-04-08 2018-07-20 王长国 一种tlr7激动剂在增强cik细胞对肿瘤细胞杀伤力方面的应用
WO2020232226A1 (en) 2019-05-16 2020-11-19 The Johns Hopkins University Compositions and methods for skin rejuvenation
CN111117966A (zh) * 2020-03-02 2020-05-08 南通大学 一种利用乳酸的体外细胞培养方法
CN111579538B (zh) * 2020-04-22 2022-12-30 山东第一医科大学(山东省医学科学院) 一种利用凋亡试剂盒检测循环肿瘤细胞的方法
EP4327821A4 (en) * 2021-05-24 2025-07-23 Cha Vaccine Res Institute Co Ltd IMMUNO-ONCOLOGY THERAPEUTIC COMPOSITION USING AN ADJUVANT COMPRISING LIPOPEPTIDES AND POLY (I:C)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
CN1040504A (zh) * 1988-06-22 1990-03-21 Hem研究公司 用双链核糖核酸调节淋巴激活素抗性细胞状态
RU2136278C1 (ru) * 1998-04-07 1999-09-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Противоопухолевое средство
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
AU2002360243A1 (en) * 2001-07-26 2003-05-06 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
WO2004047612A2 (en) * 2002-11-22 2004-06-10 Nuvelo, Inc. Methods of therapy and diagnosis
JP3810731B2 (ja) * 2002-11-29 2006-08-16 独立行政法人科学技術振興機構 哺乳動物のＴｏｌｌ様受容体３に結合する新規アダプタータンパク質およびその遺伝子

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101250419B1 (ko) * 2010-12-16 2013-04-05 강원대학교산학협력단 Ｔｌｒ 작동제를 포함하는 유방암 방사선 치료 보조제

Also Published As

Publication number Publication date
MX2007000770A (es) 2007-03-26
US20090285779A1 (en) 2009-11-19
US20060147456A1 (en) 2006-07-06
RU2007105987A (ru) 2008-08-27
JP2008507530A (ja) 2008-03-13
EP1768699A1 (en) 2007-04-04
NO20070945L (no) 2007-02-19
CN101018567B (zh) 2011-07-27
AU2005269733B2 (en) 2008-10-30
RU2401661C9 (ru) 2011-01-27
RU2401661C2 (ru) 2010-10-20
CA2574176A1 (en) 2006-02-09
AU2008249173A1 (en) 2008-12-11
CN101018567A (zh) 2007-08-15
AU2005269733A1 (en) 2006-02-09
WO2006014653A1 (en) 2006-02-09
ATE511859T1 (de) 2011-06-15

Similar Documents

Publication Publication Date Title
KR20070043795A (ko) 톨-유사 수용체 발현 종양 세포에서 세포자멸사의 유도방법
US20240043541A1 (en) Methods for treating hematologic cancers
Jing et al. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer
US11207393B2 (en) Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
US20090191185A1 (en) Reducing Cancer Cell Invasion Using an Inhibitor of Toll Like Receptor Signaling
US20150132226A1 (en) Treatment of cancer
Luo et al. Activation of Toll-like receptor 3 induces apoptosis of oral squamous carcinoma cells in vitro and in vivo
TW201919706A (zh) 包含ｉｌ－３３拮抗劑的子宮內膜異位症治療劑
Kulshrestha et al. In vivo anti‐V‐ATPase antibody treatment delays ovarian tumor growth by increasing antitumor immune responses
WO2017139468A1 (en) Combination of ifn-gamma with erbb inhibitor for the treatment of cancers
Antony et al. PD-1/PD-L1 blockade inhibits epithelial-mesenchymal transition and improves chemotherapeutic response in breast cancer
JP2022502517A (ja) ヒトｄｉｃｋｋｏｐｆ３に対するモノクローナル抗体およびその使用方法
US20140348744A1 (en) Compositions and methods for regulating cancer-related signaling pathways
Wang et al. Nifuroxazide in combination with CpG ODN exerts greater efficacy against hepatocellular carcinoma
TWI730450B (zh) 抗體，包含該抗體的套組，以及其用途
JP5695905B2 (ja) Ｎｌｒｒ−１アンタゴニスト及びその使用
US20210340274A1 (en) Targeting CLPTMIL for Treatment and Prevention of Cancer
US9868792B2 (en) Methods of enhancing anti-tumor immunity by administering antibodies to the CCRL2 chemerin receptor
KR20180125906A (ko) 항암 치료 효과 증진용 약학 조성물
JP2010540653A5 (enExample)
US20230331849A1 (en) CpG IMMUNOCONJUGATES FOR CANCER THERAPY
WO2022192528A1 (en) Gal3bp polypeptide compositions and methods for treatment of cancer and determining treatment responsiveness
Lohmann et al. Interferon-฀ sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02
Parihar Characterization of the natural killer cell cytokine response to antibody-coated tumor cells
TW201919694A (zh) Ｃｄ１４拮抗分子用於治療癌症

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070119

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100715

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120523

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120726

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120523

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I